STOCK TITAN

Attovia Therapeutics (ATTO) adopts amended charter and bylaws with IPO

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Attovia Therapeutics, Inc. implemented an Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws on August 6, 2026, in connection with the closing of its initial public offering of common stock, par value $0.0001 per share. The board of directors and stockholders had previously approved these revised governing documents to become effective immediately prior to the offering’s closing, as described in the company’s final prospectus dated August 4, 2026. The company’s common stock trades under the symbol ATTO on the Nasdaq Global Market.

Positive

  • None.

Negative

  • None.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Charter and bylaws effective date August 6, 2026 Date amended and restated charter and bylaws became effective with IPO closing
Par value per share $0.0001 per share Par value of Attovia Therapeutics common stock
Trading symbol ATTO Ticker for common stock on the Nasdaq Global Market
Amended and Restated Certificate of Incorporation regulatory
"filed its Amended and Restated Certificate of Incorporation (the “Charter”)"
A company’s amended and restated certificate of incorporation is an updated version of its foundational legal charter that replaces the older document and folds in all changes into one clear copy; it spells out corporate structure, classes of stock, shareholder rights and key governance rules. Investors care because it can change who controls the company, how votes are counted, what claims shareholders have on assets or dividends, and can introduce or remove protections against takeovers—like updating a house title after a major renovation to show who owns what and under what rules.
Amended and Restated Bylaws regulatory
"its Amended and Restated Bylaws (the “Bylaws”) became effective"
A company’s amended and restated bylaws are its internal rulebook rewritten to include all changes in one updated document, replacing the old bylaws. For investors, this matters because the bylaws set how the board, shareholders and officers make decisions, hold votes and handle disputes; a new consolidated version can change voting rights, control mechanisms or procedures that affect corporate governance and the value or risk of an investment.
initial public offering financial
"in connection with the closing of the initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
Description of Capital Stock financial
"set forth in the section titled “Description of Capital Stock” in the Prospectus"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What corporate changes did Attovia Therapeutics (ATTO) implement on August 6, 2026?

Attovia Therapeutics implemented an Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws on August 6, 2026, timed to become effective immediately prior to the closing of its initial public offering of common stock.

How are Attovia Therapeutics’ (ATTO) new charter and bylaws linked to its IPO?

The updated charter and bylaws were approved by the board and stockholders to be effective immediately prior to the IPO closing, aligning the company’s corporate governance framework with its status as a newly public company following the initial public offering.

Where can investors find details of Attovia Therapeutics’ (ATTO) charter and bylaws provisions?

Key provisions of the charter and bylaws are described in the “Description of Capital Stock” section of Attovia Therapeutics’ final prospectus dated August 4, 2026, which accompanied its registration statement for the initial public offering.

What is the par value and exchange listing for Attovia Therapeutics (ATTO) common stock?

Attovia Therapeutics’ common stock has a par value of $0.0001 per share and is listed for trading on the Nasdaq Global Market under the ticker symbol ATTO, as identified in the company’s disclosure.

Who signed the corporate governance update for Attovia Therapeutics (ATTO)?

The report documenting the charter and bylaws changes was signed on behalf of Attovia Therapeutics by Steven Chan, the company’s Chief Financial Officer, dated August 6, 2026, confirming the company’s authorization of the disclosed governance actions.
--12-31 false 0002058707 0002058707 2026-08-06 2026-08-06
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2026

 

 

Attovia Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-43423   92-1510574

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

1091 Industrial Road, Suite 310

San Carlos, California 94070

(Address of principal executive offices) (Zip Code)

(510) 399-5001

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common stock, $0.0001 par value per share   ATTO   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 
 


Item 5.03

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On August 6, 2026, Attovia Therapeutics, Inc. (the “Company”) filed its Amended and Restated Certificate of Incorporation (the “Charter”) with the Secretary of State of the State of Delaware and its Amended and Restated Bylaws (the “Bylaws”) became effective in connection with the closing of the initial public offering (the “Offering”) of shares of the Company’s common stock, par value $0.0001 per share. As described in the final prospectus, dated August 4, 2026 (the “Prospectus”), relating to the Registration Statement on Form S-1 (File No. 333-297452, as amended), filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, the Company’s board of directors and stockholders previously approved the amendment and restatement of these documents to be effective immediately prior to the closing of the Company’s Offering. A description of certain provisions of the Charter and the Bylaws is set forth in the section titled “Description of Capital Stock” in the Prospectus. The foregoing description of the Charter and the Bylaws is qualified in its entirety by reference to (1) the Charter filed as Exhibit 3.1 hereto and (2) the Bylaws filed as Exhibit 3.2 hereto, each of which is incorporated herein by reference.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.

  

Description

 3.1    Amended and Restated Certificate of Incorporation of Attovia Therapeutics, Inc.
 3.2    Amended and Restated Bylaws of Attovia Therapeutics, Inc.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ATTOVIA THERAPEUTICS, INC.
Date: August 6, 2026     By:  

/s/ Steven Chan

    Name:   Steven Chan
    Title:   Chief Financial Officer

Filing Exhibits & Attachments

5 documents